Cutia Therapeutics (HKG:2487) said its chief executive officer, Zhang Lele, purchased 5,000 shares of the company through the open market for HK$49,280, according to a Monday filing with the Hong Kong bourse.

Zhang also bought 28,000 shares of the company in October for HK$343,932 and has not ruled out the possibility of further purchases.

These aggregate purchases of shares stood at 33,000 shares for a total of HK$393,212, with an average price of about HK$11.916 per share.